Mika K Derynck

Author PubWeight™ 8.20^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor.	Proc Natl Acad Sci U S A	2003	2.63
2	Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.	J Clin Oncol	2004	2.02
3	Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.	J Clin Oncol	2006	1.65
4	Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.	J Clin Oncol	2007	1.14
5	A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.	Clin Genitourin Cancer	2007	0.96